Honasa buys 58% of Fluence Pharma for ₹135 Cr, enters nutraceuticals via Honasa Health
Mamaearth parent acquires majority in Fluence Pharma (FY25 revenue ₹37.2 Cr), launching subsidiary Honasa Health to crack the ₹16,000 Cr Indian nutraceuticals market. Move backs Honasa 3.0 plan targeting ₹5,500 Cr revenue by FY31, with remaining 42% to be picked up over 5-7 years.
Honasa Consumer acquires 58% of nutraceuticals firm Fluence Pharma for ₹135 Cr, entering supplements via new subsidiary Honasa Health. Move aligns with Honasa 3.0 strategy targeting ₹5,500 Cr FY31 revenue and expansion beyond Mamaearth into nutrition, fragrances, oral care.
Why this matters
Honasa is diversifying beyond Mamaearth's BPC core into health and wellness, using Fluence Pharma as the platform to operationalize its Honasa 3.0 growth roadmap toward ₹5,500 Cr by FY31.
Retail-company activity steady with 3,569 signals over the last 90 days.
Also reported by
- Inc42 — Same time